Northern Trust’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Northern Trust’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,432	Closed	-$75.2K	–	4499
2023 Q4	$75.2K	Buy	6,432 +4,959	+337%	+$66.5K	﹤0.01%	4164
2023 Q3	$22.1K	Buy	1,473 +433	+42%	+$7.52K	﹤0.01%	4317
2023 Q2	$21.6K	Hold	1,040	–	–	﹤0.01%	4396
2023 Q1	$9.17K	Hold	1,040	–	–	﹤0.01%	4530
2022 Q4	$11.1K	Hold	1,040	–	–	﹤0.01%	4562
2022 Q3	$15K	Hold	1,040	–	–	﹤0.01%	4595
2022 Q2	$37K	Buy	1,040 +370	+55%	+$22.4K	﹤0.01%	4493
2022 Q1	$67K	Buy	670 +4	+0.6%	+$532	﹤0.01%	4461
2021 Q4	$138K	Buy	+666	New	+$155K	﹤0.01%	4323

Other funds holding EFTR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Northern Trust's EFTR Position: Q1 2024 in Review

Northern Trust sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 6,432 shares — an estimated $75.2K sold.

Northern Trust first reported a position in EFTR in Q4 2021 and held it in 9 quarters. The position peaked at $138K in Q4 2021. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

Northern Trust reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Northern Trust sold 6,432 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $75.2K.
Northern Trust first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Northern Trust's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $138K in Q4 2021.
17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.